High Expression of PKM2 Was Associated with the Poor Prognosis of Acute Leukemia

References

• Gao J, Wang F, Wu P, Chen Y, Jia Y. Aberrant LncRNA expression in leukemia. J Cancer. 2020;11(14):4284–4296. doi:10.7150/jca.4209332368311
   PubMed Web of Science ®Google Scholar
• Cazzola M. Introduction to a review series: the 2016 revision of the WHO classification of tumors of hematopoietic and lymphoid tissues. Blood. 2016;127(20):2361–2364. doi:10.1182/blood-2016-03-65737927069255
   PubMed Web of Science ®Google Scholar
• Soverini S, Bassan R, Lion T. Treatment and monitoring of Philadelphia chromosome-positive leukemia patients: recent advances and remaining challenges. J Hematol Oncol. 2019;12(1):39. doi:10.1186/s13045-019-0729-231014376
   PubMed Web of Science ®Google Scholar
• Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391–2405. doi:10.1182/blood-2016-03-64354427069254
   PubMed Web of Science ®Google Scholar
• Nguyen TV, Melville A, Nath S, et al. Bone marrow recovery by morphometry during induction chemotherapy for acute lymphoblastic leukemia in children. PLoS One. 2015;10(5):e0126233. doi:10.1371/journal.pone.012623325962143
   PubMed Web of Science ®Google Scholar
• Bain BJ. Morbidity associated with bone marrow aspiration and trephine biopsy - a review of UK data for 2004. Haematologica. 2006;91(9):1293–1294.16956842
   PubMed Web of Science ®Google Scholar
• Li C, Zhao Z, Zhou Z, Liu R. PKM2 promotes cell survival and invasion under metabolic stress by enhancing Warburg effect in pancreatic ductal adenocarcinoma. Dig Dis Sci. 2016;61(3):767–773. doi:10.1007/s10620-015-3931-226500118
   PubMed Web of Science ®Google Scholar
• Mazurek S. Pyruvate kinase type M2: a key regulator of the metabolic budget system in tumor cells. Int J Biochem Cell Biol. 2011;43(7):969–980. doi:10.1016/j.biocel.2010.02.00520156581
   PubMed Web of Science ®Google Scholar
• Chen D, Wei L, Liu ZR, et al. Pyruvate kinase M2 increases angiogenesis, neurogenesis, and functional recovery mediated by upregulation of STAT3 and focal adhesion kinase activities after ischemic stroke in adult mice. Neurotherapeutics. 2018;15(3):770–784. doi:10.1007/s13311-018-0635-229869055
   PubMed Web of Science ®Google Scholar
• Stone OA, El-Brolosy M, Wilhelm K, et al. Loss of pyruvate kinase M2 limits growth and triggers innate immune signaling in endothelial cells. Nat Commun. 2018;9(1):4077. doi:10.1038/s41467-018-06406-830301887
   PubMed Web of Science ®Google Scholar
• Li YH, Li XF, Liu JT, et al. PKM2, a potential target for regulating cancer. Gene. 2018;668:48–53. doi:10.1016/j.gene.2018.05.03829775756
   PubMed Web of Science ®Google Scholar
• Zahra K, Dey T, Ashish MSP, Pandey U, Pandey U. Pyruvate kinase M2 and cancer: the role of PKM2 in promoting tumorigenesis. Front Oncol. 2020;10:159. doi:10.3389/fonc.2020.0015932195169
   PubMed Web of Science ®Google Scholar
• Zhang Z, Deng X, Liu Y, Liu Y, Sun L, Chen F. PKM2, function and expression and regulation. Cell Biosci. 2019;9(1):52. doi:10.1186/s13578-019-0317-831391918
   PubMed Web of Science ®Google Scholar
• Wang L, Yang L, Yang Z, et al. Glycolytic enzyme PKM2 mediates autophagic activation to promote cell survival in NPM1-mutated leukemia. Int J Biol Sci. 2019;15(4):882–894. doi:10.7150/ijbs.3029030906218
   PubMed Web of Science ®Google Scholar
• Xia L, Jiang Y, Zhang XH, et al. SUMOylation disassembles the tetrameric pyruvate kinase M2 to block myeloid differentiation of leukemia cells. Cell Death Dis. 2021;12(1):101. doi:10.1038/s41419-021-03400-933473116
   PubMed Web of Science ®Google Scholar
• Biswas SK. Metabolic reprogramming of immune cells in cancer progression. Immunity. 2015;43(3):435–449. doi:10.1016/j.immuni.2015.09.00126377897
   PubMed Web of Science ®Google Scholar
• Gao P, Shen S, Li X, et al. Dihydroartemisinin inhibits the proliferation of leukemia cells K562 by suppressing PKM2 and GLUT1 mediated aerobic glycolysis. Drug Des Devel Ther. 2020;14:2091–2100. doi:10.2147/DDDT.S248872
   PubMed Web of Science ®Google Scholar
• Lebelo MT, Joubert AM, Visagie MH. Warburg effect and its role in tumourigenesis. Arch Pharm Res. 2019;42(10):833–847. doi:10.1007/s12272-019-01185-231473944
   PubMed Web of Science ®Google Scholar
• Wu H, Zhao H, Chen L. Deoxyshikonin inhibits viability and glycolysis by suppressing the Akt/mTOR pathway in acute myeloid leukemia cells. Front Oncol. 2020;10:1253. doi:10.3389/fonc.2020.0125332850379
   PubMed Web of Science ®Google Scholar
• Wang Y, Zhao H, Zhao P, Wang X. Targeting PKM2 promotes chemosensitivity of breast cancer cells in vitro and in vivo. Cancer Biomarker. 2021;32(2):221–230. doi:10.3233/CBM-210111
   PubMed Web of Science ®Google Scholar
• Apostolidi M, Vathiotis IA, Muthusamy V, et al. Targeting pyruvate kinase M2 phosphorylation reverses aggressive cancer phenotypes. Cancer Res. 2021;81(16):4346–4359. doi:10.1158/0008-5472.CAN-20-419034185676
   PubMed Web of Science ®Google Scholar
• Li Z, Yang P, Li Z. The multifaceted regulation and functions of PKM2 in tumor progression. Biochim Biophys Acta. 2014;1846(2):285–296. doi:10.1016/j.bbcan.2014.07.00825064846
   PubMed Web of Science ®Google Scholar
• Gao X, Wang H, Yang JJ, Liu X, Liu ZR. Pyruvate kinase M2 regulates gene transcription by acting as a protein kinase. Mol Cell. 2012;45(5):598–609. doi:10.1016/j.molcel.2012.01.00122306293
   PubMed Web of Science ®Google Scholar
• Wong N, Ojo D, Yan J, Tang D. PKM2 contributes to cancer metabolism. Cancer Lett. 2015;356(2Pt A):184–191. doi:10.1016/j.canlet.2014.01.03124508027
   PubMed Web of Science ®Google Scholar
• Sun ML, Wang GJ, Li J, et al. [Construction of shRNA eukaryotic expression vectors of pkm2 gene and their effect on drug resistant cell line of acute promyelocytic leukemia]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2010;18(1):85–89. Chinese.20137124
   PubMedGoogle Scholar
• Cicconi L, Fenaux P, Kantarjian H, Tallman M, Sanz MA, Lo-Coco F. Molecular remission as a therapeutic objective in acute promyelocytic leukemia. Leukemia. 2018;32(8):1671–1678. doi:10.1038/s41375-018-0219-530026570
   PubMed Web of Science ®Google Scholar
• Organista-Nava J, Gomez-Gomez Y, Illades-Aguiar B, Leyva-Vazquez MA. Regulation of the miRNA expression by TEL/AML1, BCR/ ABL,MLL/AF4 and TCF3/PBX1 oncoproteins in acute lymphoblastic leukemia (Review). Oncol Rep. 2016;36(3):1226–1232. doi:10.3892/or.2016.494827431573
   PubMed Web of Science ®Google Scholar
• Ren R. Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia. Nat Rev Cancer. 2005;5(3):172–183. doi:10.1038/nrc156715719031
   PubMed Web of Science ®Google Scholar
• Niu Y, Yang X, Chen Y, et al. EVI1 induces autophagy to promote drug resistance via regulation of ATG7 expression in leukemia cells. Carcinogenesis. 2020;41(7):961–971. doi:10.1093/carcin/bgz16731593983
   PubMed Web of Science ®Google Scholar
• Shinohara H, Taniguchi K, Kumazaki M, et al. Anti-cancer fatty-acid derivative induces autophagic cell death through modulation of PKM isoform expression profile mediated by bcr-abl in chronic myeloid leukemia. Cancer Lett. 2015;360(1):28–38. doi:10.1016/j.canlet.2015.01.03925644089
   PubMed Web of Science ®Google Scholar
• De Rosa V, Monti M, Terlizzi C, Fonti R, Del Vecchio S, Iommelli F. Coordinate modulation of glycolytic enzymes and OXPHOS by imatinib in BCR-ABL driven chronic myelogenous leukemia cells. Int J Mol Sci. 2019;20(13):3134. doi:10.3390/ijms20133134
   PubMed Web of Science ®Google Scholar